$62.24
1.121.83%
Last update: Oct 8, 3:41 PM
$60.55
-0.57-0.93%
Cytokinetics Inc
CYTKNASDAQ
Cytokinetics (CYTK) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Cytokinetics (CYTK) last issued guidance on February 27, 2024 for fiscal year 2024. The company guided revenue in the range of $3M - $5M for the period.
Compared to prior guidance, Cytokinetics lowered its revenue forecast from a prior range of $5M - $5M.
Cytokinetics has issued 2 guidance updates between March 1, 2023 and February 27, 2024. During this period, the company lowered its outlook 1 time, signaling management's revised expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-1.62 | $-1.65 | $-1.41 | $-1.58 |
| Actual | $-1.50 | $-1.67 | $-1.50 | $-1.54 |
| Surprise | +7.41% | -1.21% | -6.38% | +2.53% |
| Revenue | ||||
| Estimate | $17.2M | $8.5M | $6.4M | $5.9M |
| Actual | $28.6M | $19.4M | $17.8M | $1.9M |
| Surprise | +66.0% | +128.1% | +178.7% | -66.9% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-1.45 | $-1.43 | $-1.46 | $-1.33 |
| Revenue | ||||
| Consensus | $40.2M | $59.8M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $-1.50 | $-1.62 | 7.41 % |
| Q1 | May 5, 2026 | $-1.67 | $-1.65 | -1.21 % |
| Q4 | Feb 24, 2026 | $-1.50 | $-1.41 | -6.38 % |
| Q3 | Nov 5, 2025 | $-1.54 | $-1.58 | 2.53 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $28.62M | $17.24M | 66.0 % |
| Q1 | May 5, 2026 | $19.36M | $8.49M | 128.1 % |
| Q4 | Feb 24, 2026 | $17.76M | $6.37M | 178.7 % |
| Q3 | Nov 5, 2025 | $1.94M | $5.85M | -66.9 % |
